哥伦布部分1-7年的结果：encorafenib和binimetinib治疗BRAF v600突变黑色素瘤。

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-24 DOI:10.1080/14796694.2025.2536459

Dirk Schadendorf

引用次数: 0

摘要

本摘要介绍了COLUMBUS第1部分的7年结果，该部分测试了encorafenib （BRAFTOVI®）和binimetinib （MEKTOVI®）（COMBO组）单独治疗encorafenib （ENCO组）或vemurafenib （ZELBORAF®）单独治疗（VEMU组）作为晚期或转移性BRAF v600突变黑色素瘤的皮肤癌的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma.

This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called advanced or metastatic BRAF V600-mutant melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.